Skip to main content
SpringerLink
Log in

Oteseconazole: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections. It inhibits cytochrome P450 (CYP) 51, thereby affecting the formation and integrity of the fungal cell membrane, but has a low affinity for human CYP enzymes due to its tetrazole metal-binding group. Oteseconazole is the first agent to be approved (in April 2022) for recurrent vulvovaginal candidiasis (RVVC) in the USA, where it is indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential. Clinical development for the treatment of onychomycosis, and invasive and opportunistic infections is ongoing. This article summarizes the milestones in the development of oteseconazole leading to this first approval for reducing the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cooke G, Watson C, Deckx L, et al. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst Rev. 2022;1:CD009151.

    PubMed  Google Scholar 

  2. Mycovia Pharmaceuticals. FDA approves Mycovia Pharmaceuticals VIVJOA™ (oteseconazole), the first and only FDA-approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection) [media release]. 28 Apr 2022. https://mycovia.com/.

  3. Mycovia Pharmaceuticals. VIVJOA™ (oteseconazole) capsules, for oral use. 2022. https://www.fda.gov/. Accessed 29 Apr 2022.

  4. Mycovia Pharmaceuticals, Jiangsu Hengrui Medicine. Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announce partnership to develop and commercialize VT-1161 for recurrent vulvovaginal candidiasis and other fungal conditions [media release]. 17 Jun 2019. https://mycovia.com/.

  5. Mycovia Pharmaceuticals. Mycovia Pharmaceuticals announces partnership with Gedeon Richter to commercialize and manufacture VT-1161 for recurrent vulvovaginal candidiasis [media release]. 16 Oct 2019. https://mycovia.com/.

  6. Warrilow AG, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121–7.

    Article  CAS  Google Scholar 

  7. Ghannoum M, Degenhardt T, Person K. Susceptibility testing of oteseconazole (VT-1161) against clinical isolates from phase 3 clinical studies in subjects with recurrent vulvovaginal candidiasis [abstract no. 719]. Open Forum Infect Dis. 2021;8(Suppl 1):S459.

    Article  Google Scholar 

  8. Wang L, Zhang M, Guo J, et al. In vitro activities of the tetrazole VT-1161 compared with itraconazole and fluconazole against Cryptococcus and non-albicans Candida species. Mycologia. 2021;113(5):918–25.

    CAS  PubMed  Google Scholar 

  9. Garvey EP, Hoekstra WJ, Schotzinger RJ, et al. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59(9):5567–73.

    Article  CAS  Google Scholar 

  10. Monk BC, Keniya MV, Sabherwal M, et al. Azole resistance reduces susceptibility to the tetrazole antifungal VT-1161. Antimicrob Agents Chemother. 2019;63(1):e02114-e2118.

    Article  CAS  Google Scholar 

  11. Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63:e00341-e419.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017;61(3):e01817-e1916.

    Article  CAS  Google Scholar 

  13. Nishimoto AT, Whaley SG, Wiederhold NP, et al. Impact of the major Candida glabrata triazole resistance determinants on the activity of the novel investigational tetrazoles VT-1598 and VT-1161. Antimicrob Agents Chemother. 2019;63:e01304-e1319.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. US FDA Center for Drug Evaluation and Research. Integrated review. 2022. https://www.fda.gov/. Accessed 26 May 2022.

  15. Person K, Brand S, Degenhardt T, et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oteseconazole (VT-1161) oral capsules in the treatment of subjects with recurrent vulvovaginal candidiasis (VIOLET) [abstract no. 5]. Am J Obstet Gynecol. 2022;226(2):292.

    Article  Google Scholar 

  16. Martens MG, Maximos B, Degenhardt T, et al. A phase 3, randomized, double-blind study to evaluate the efficacy and safety of oteseconazole (VT-1161) oral capsules versus fluconazole and placebo in the treatment of acute vulvovaginal candidiasis episodes in subjects with recurrent vulvovaginal candidiasis (ultraVIOLET) [abstract no. 107]. Open Forum Infect Dis. 2021;8(Suppl 1):S66–7.

    Article  Google Scholar 

  17. Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.e1-e9.

    Article  Google Scholar 

  18. Brand SR, Sobel JD, Nyirjesy P, et al. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2021;73(7):e1518–24.

    Article  CAS  Google Scholar 

  19. Elewski B, Brand S, Degenhardt T, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail. Br J Dermatol. 2021;184(2):270–80.

    Article  CAS  Google Scholar 

  20. Mycovia Pharmaceuticals. Mycovia Pharmaceuticals initiates extension clinical studies to further evaluate long-term efficacy of oteseconazole (VT-1161) in patients with recurrent vulvovaginal candidiasis [media release]. 11 Feb 2020. http://www.mycovia.com.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sheridan M. Hoy

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. M. Hoy is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 502 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoy, S.M. Oteseconazole: First Approval. Drugs 82, 1017–1023 (2022). https://doi.org/10.1007/s40265-022-01734-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-022-01734-y

Search

Navigation